{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:04:49Z","timestamp":1772816689989,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008992","name":"Yantai University","doi-asserted-by":"publisher","award":["2222012"],"award-info":[{"award-number":["2222012"]}],"id":[{"id":"10.13039\/100008992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.118044","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:11:17Z","timestamp":1754435477000},"page":"118044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and evaluation of novel 5-HT2A receptor inverse agonist with excellent in vivo antipsychotic efficacy and superior tissue distribution for treatment of Parkinson's disease psychosis"],"prefix":"10.1016","volume":"298","author":[{"given":"Mingxu","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonglin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9423","key":"10.1016\/j.ejmech.2025.118044_bib1","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson's disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"issue":"9996","key":"10.1016\/j.ejmech.2025.118044_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118044_bib3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbi.2020.01.009","article-title":"Regulation of immune-driven pathogenesis in Parkinson's disease by gut microbiota","volume":"87","author":"Zheng","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejmech.2025.118044_bib4","volume":"vol 2021","author":"Dashtipour","year":"2021"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118044_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jagp.2018.06.001","article-title":"Perspective on pimavanserin and the SAPS-PD: novel scale development as a means to FDA approval","volume":"26","author":"Schubmehl","year":"2018","journal-title":"Am. J. Geriatr. Psychiatr."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118044_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin (2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2025.118044_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/NDT.S108948","article-title":"Update on the treatment of Parkinson's disease psychosis: role of pimavanserin","volume":"13","author":"Combs","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118044_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1358\/dot.2015.51.11.2404001","article-title":"Pimavanserin","volume":"51","author":"Hunter","year":"2015","journal-title":"Drugs Today"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118044_bib9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118044_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/FBP.0b013e3283566082","article-title":"A 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease","volume":"23","author":"Price","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118044_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114246","article-title":"Improving the treatment of Parkinson's disease: structure-based development of novel 5-HT2A receptor antagonists\/inverse agonists","volume":"234","author":"Ma","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2025.118044_bib12","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1021\/acs.jmedchem.3c00662","article-title":"Design, synthesis, molecular docking, and biological evaluation of novel pimavanserin-based analogues as potential serotonin 5-HT2A receptor inverse agonists","volume":"66","author":"Albujuq","year":"2023","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118044_bib13","doi-asserted-by":"crossref","first-page":"14478","DOI":"10.1021\/acs.jmedchem.4c01244","article-title":"Dual 5-HT2A and 5-HT2C receptor inverse agonist that affords in vivo antipsychotic efficacy with minimal hERG inhibition for the treatment of dementia-related psychosis","volume":"67","author":"Oguma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118044_bib14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1747519819873643","article-title":"An improved process for the preparation of pimavanserin tartrate","volume":"43","author":"Wu","year":"2019","journal-title":"J. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118044_bib15","unstructured":"K. Dinnell, A.P. Lightfoot, H.R. Marshall. Preparation of Indoles as Modulators of Nicotinic Acetylcholine Receptor Subtype \u03917. WO2009127678."},{"key":"10.1016\/j.ejmech.2025.118044_bib16","unstructured":"J.W. Tian, L. Ye, M.X. Ma, et al. 5-HT2A Receptor Inverse Agonist, its Preparation Method and Application. WO2024027800."},{"key":"10.1016\/j.ejmech.2025.118044_bib17","doi-asserted-by":"crossref","first-page":"9346","DOI":"10.1021\/jm3009025","article-title":"Design and synthesis of \u03b2-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of \u03b2-amyloid peptides","volume":"55","author":"Swahn","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118044_bib18","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1021\/jm9009857","article-title":"Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo [3, 2-c] pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain","volume":"52","author":"Giblin","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118044_bib19","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1021\/jm200956q","volume":"54","author":"Jones","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118044_bib20","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.bmcl.2005.06.107","article-title":"Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists","volume":"15","author":"Ahmed","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118044_bib21","first-page":"469","article-title":"What has polar surface area ever done for drug discovery? Fut","volume":"3","author":"Clark","year":"2011","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118044_bib22","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1021\/jm201136z","article-title":"Structural modifications that alter the P-glycoprotein efflux properties of compounds","volume":"55","author":"Hitchcock","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118044_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pbb.2011.04.003","article-title":"Role of endocannabinoid and glutamatergic systems in DOI-induced head-twitch response in mice","volume":"99","author":"Egashira","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2025.118044_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/7854_2016_466","article-title":"Effect of hallucinogens on unconditioned behavior","volume":"36","author":"Halberstadt","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2025.118044_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejphar.2007.02.031","article-title":"Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT2A\/2C receptors","volume":"564","author":"Su","year":"2007","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:56:26Z","timestamp":1772794586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"alternative-id":["S0223523425008098"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118044","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of novel 5-HT2A receptor inverse agonist with excellent in vivo antipsychotic efficacy and superior tissue distribution for treatment of Parkinson's disease psychosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118044"}}